More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.70B
EPS
-5.18
P/E ratio
--
Price to sales
2.13
Dividend yield
--
Beta
0.369677
Previous close
$15.90
Today's open
$15.94
Day's range
$15.65 - $16.74
52 week range
$12.73 - $39.89
show more
CEO
Emil D. Kakkis
Employees
1371
Headquarters
Novato, CA
Exchange
Nasdaq Global Select
Shares outstanding
101924068
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
Ultragenyx Pharmaceutical NASDAQ: RARE expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Biopharma Conference.
MarketBeat • Nov 17, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Ultragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold
I initiate coverage of Ultragenyx Pharmaceutical with a Hold rating and $18 price target, citing a credible valuation floor but limited near-term catalysts. Two major late-stage pipeline failures have reset investor sentiment, and I see few meaningful catalysts over the next 12 months. RARE's legacy business is stable, but new gene therapies face payer pushback, tiny patient pools, and unproven durability, posing long-term risks.
Seeking Alpha • Nov 12, 2026

Ultragenyx to Participate at Investor Conferences in London
NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in upcoming investor conferences.
GlobeNewsWire • Nov 11, 2026

Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA)
BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted on 28th October 2026 the Company's Marketing Authorisation Application (MAA) for rebisufligene etisparvovec (also known as rebi-vec or UX111), an investigational gene therapy for the treatment of mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A.
GlobeNewsWire • Nov 6, 2026

Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock is trading lower on Wednesday after the company initiated substantial expense reductions to align expenses with revenue and achieve profitability by 2027.
Benzinga • Nov 4, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CEO & Director Howard Horn - Executive VP of Corporate Strategy & CFO Erik Harris - Executive VP & Chief Commercial Officer Eric Crombez - Chief Medical Officer & Executive VP Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Joon Lee Jaena Han - TD Cowen, Research Division Tazeen Ahmad - BofA Securities, Research Division Maxwell Skor - Morgan Stanley, Research Division Lydia Erdman - Goldman Sachs Group, Inc., Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Luca Issi - RBC Capital Markets, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.
Seeking Alpha • Nov 4, 2026

Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot
Ultragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains highly concentrated in CRYSVITA, with new launches contributing minimally. Pipeline setbacks and terminated programs have forced a pivot from high-risk optionality to a leaner rare-disease commercial model.
Seeking Alpha • Nov 4, 2026

What Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
Ultragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions intended to support GAAP profitability in 2027.
MarketBeat • Nov 4, 2026

Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) under agreement for combined sales price of $413 million Substantial reduction of expenses and headcount underway, expected to drive at least a 50% reduction in 2027 R&D expenses vs 2025 NOVATO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended September 30, 2026, announced substantial expense reductions, and reaffirmed its guidance for 2026 revenue and 2027 profitability.
GlobeNewsWire • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Ultragenyx Pharmaceutical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.